PTPRC and neoplasm: Furthermore, co-administration of Fbp1 knockdown and anti-pd-l1 antibody additively increased the tumor infiltration of CD45+CD8+ T and CD45+CD4+ T cells and a substantial reduction of CD11b+Gr1+ MDSCs (Figure 6E).